JP4578770B2 - 細胞質中への分子送達のための光化学的内在化 - Google Patents

細胞質中への分子送達のための光化学的内在化 Download PDF

Info

Publication number
JP4578770B2
JP4578770B2 JP2002546744A JP2002546744A JP4578770B2 JP 4578770 B2 JP4578770 B2 JP 4578770B2 JP 2002546744 A JP2002546744 A JP 2002546744A JP 2002546744 A JP2002546744 A JP 2002546744A JP 4578770 B2 JP4578770 B2 JP 4578770B2
Authority
JP
Japan
Prior art keywords
molecule
cells
cell
photosensitizer
irradiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002546744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004520021A5 (https=
JP2004520021A (ja
Inventor
クリスティン バーグ
リーナ プラスミケイト
アンダース ホッグセット
パル クリスティン セルボ
Original Assignee
ピーシーアイ バイオテック エイエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0029134A external-priority patent/GB0029134D0/en
Priority claimed from GB0029404A external-priority patent/GB0029404D0/en
Priority claimed from GB0114695A external-priority patent/GB0114695D0/en
Application filed by ピーシーアイ バイオテック エイエス filed Critical ピーシーアイ バイオテック エイエス
Publication of JP2004520021A publication Critical patent/JP2004520021A/ja
Publication of JP2004520021A5 publication Critical patent/JP2004520021A5/ja
Application granted granted Critical
Publication of JP4578770B2 publication Critical patent/JP4578770B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2002546744A 2000-11-29 2001-11-29 細胞質中への分子送達のための光化学的内在化 Expired - Fee Related JP4578770B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0029134A GB0029134D0 (en) 2000-11-29 2000-11-29 Method
GB0029404A GB0029404D0 (en) 2000-12-01 2000-12-01 Method
GB0114695A GB0114695D0 (en) 2001-06-15 2001-06-15 Method
PCT/GB2001/005299 WO2002044396A1 (en) 2000-11-29 2001-11-29 Photochemical internalization for delivery of molecules into the cytosol

Publications (3)

Publication Number Publication Date
JP2004520021A JP2004520021A (ja) 2004-07-08
JP2004520021A5 JP2004520021A5 (https=) 2009-12-24
JP4578770B2 true JP4578770B2 (ja) 2010-11-10

Family

ID=27255991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002546744A Expired - Fee Related JP4578770B2 (ja) 2000-11-29 2001-11-29 細胞質中への分子送達のための光化学的内在化

Country Status (14)

Country Link
US (2) US7223600B2 (https=)
EP (1) EP1346059B1 (https=)
JP (1) JP4578770B2 (https=)
KR (2) KR20080080685A (https=)
CN (1) CN100558903C (https=)
AU (2) AU2002220853B2 (https=)
BR (1) BR0115795A (https=)
CA (1) CA2430087C (https=)
CZ (1) CZ301427B6 (https=)
ES (1) ES2383516T3 (https=)
HU (1) HU229805B1 (https=)
PL (1) PL213560B1 (https=)
PT (1) PT1346059E (https=)
WO (1) WO2002044396A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
PT1346059E (pt) * 2000-11-29 2012-06-01 Pci Biotech As Internalização fotoquímica para distribuição de moléculas no citosol
GB0415263D0 (en) * 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
GB0613753D0 (en) * 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
RU2339414C1 (ru) * 2007-03-27 2008-11-27 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") Способ подавления роста опухолей
US8411669B2 (en) * 2008-04-18 2013-04-02 Cisco Technology, Inc. Distributed transcoding on IP phones with idle DSP channels
GB0811955D0 (en) 2008-06-30 2008-07-30 Pci Biotech As Method
US8808733B2 (en) 2009-03-31 2014-08-19 The Board Of Trustees Of The University Of Arkansas Method of controlled drug release from a liposome carrier
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
GB0914286D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Method
US9872833B2 (en) * 2011-10-07 2018-01-23 National University Corporation Tottori University Liposome composite body
US9849087B2 (en) 2011-11-08 2017-12-26 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
DK2911650T3 (da) * 2012-10-29 2019-11-18 Agency Science Tech & Res Hidtil ukendt reagens til gen-lægemiddel-terapeutika
US20160040128A1 (en) * 2013-03-15 2016-02-11 Pci Biotech As Method
EP3035969B1 (en) 2013-08-19 2022-08-03 S.M. Discovery Holdings Inc. Peptidic nanodelivery composition targeting two receptors
AU2014314149B2 (en) * 2013-08-28 2019-12-19 Pci Biotech As Compound and method for vaccination and immunisation
WO2015028575A1 (en) * 2013-08-28 2015-03-05 Pci Biotech As Immunisation method by photochemical internalisation
US10973896B2 (en) 2014-04-11 2021-04-13 Pci Biotech As Treatment or prevention of melanoma using photochemical internalization of a melanoma antigen
WO2016030529A1 (en) 2014-08-28 2016-03-03 Pci Biotech As Compound and method
GB201415250D0 (en) * 2014-08-28 2014-10-15 Pci Biotech As Compound and method
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
WO2018017954A1 (en) * 2016-07-21 2018-01-25 Rutgers, The State University Of New Jersey Antimicrobial cationic systems and methods of use
ES2841941T3 (es) 2016-10-14 2021-07-12 Pci Biotech As Tratamiento del colangiocarcinoma a través de la internalización fotoquímica de gemcitabina inducida por TPCS2a
KR101911725B1 (ko) * 2017-01-16 2018-12-28 주식회사 코어파마 적색형광단백질을 발현하는 유전자 및 틴 에틸 에티오푸르푸린을 이용한 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법
CN107029236B (zh) * 2017-04-18 2020-04-10 中国医学科学院生物医学工程研究所 一种吲哚菁绿自组装纳米疫苗及制备方法
GB201718631D0 (en) 2017-11-10 2017-12-27 Pci Biotech As Method
GB201801169D0 (en) 2018-01-24 2018-03-07 Pci Biotech As Method
WO2020017962A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.
CA3109804A1 (en) 2018-08-16 2020-02-20 The Regents Of The University Of California Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof
CA3133410A1 (en) 2019-04-25 2020-10-29 Dcprime B.V. Methods of tumor vaccination
CN115916963A (zh) 2020-03-27 2023-04-04 门德斯有限公司 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
US20210322471A1 (en) 2020-03-27 2021-10-21 Dcprime B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CA3196677A1 (en) 2020-11-05 2022-05-12 Erik Hans MANTING Use of tumor-independent antigens in immunotherapies
JP2024506249A (ja) 2021-01-22 2024-02-13 メンドゥス・ベスローテン・フェンノートシャップ 腫瘍ワクチン接種の方法
CA3212351A1 (en) 2021-03-12 2022-09-15 Mendus B.V. Methods of vaccination and use of cd47 blockade
GB202115451D0 (en) 2021-10-27 2021-12-08 Pci Biotech As Method

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
DK168690B1 (da) 1985-04-30 1994-05-24 Nippon Petrochemicals Co Ltd Farmaceutiske præparater til detektion og/eller behandling af pattedyrtumorer
NO891491D0 (no) 1987-08-12 1989-04-11 Peter Nemeth Prosedyre for befrielse av celleblandinger og vev for uoenskede populasjoner.
GB8721108D0 (en) 1987-09-08 1987-10-14 Salford University Of Liposomes
NO176947C (no) 1988-07-06 1995-06-28 Long Island Jewish Medical Ct Fremgangsmåte for fremstilling av et topisk preparat for fotodynamisk terapi
US5059619A (en) 1989-06-14 1991-10-22 Quadra Logic Technologies, Inc. Stable freeze-dried polyhematoporphyrin ether/ester
NO179410C (no) 1989-07-17 1996-10-02 Univ British Columbia Analogifremgangsmåte for fremstilling av terapeutisk aktive monobenzofyriner og anvendelse av disse
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5179120A (en) 1991-06-28 1993-01-12 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
PL165249B1 (pl) 1991-10-29 1994-11-30 Wojskowa Akad Tech Sposób otrzymywania soli kompleksowych hematoporfiryny i jej pochodnych PL PL PL PL PL PL PL
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9318841D0 (en) 1993-09-10 1993-10-27 Res Foundation Of The Norwegia Composition
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
HU225148B1 (en) 1995-03-10 2006-07-28 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy or diagnosis, products and kits comprising thereof and method of in vitro diagnosis by their using
GB9700396D0 (en) 1997-01-10 1997-02-26 Photocure As Photochemotherapeutic compositions
CZ294715B6 (cs) * 1997-05-07 2005-02-16 Qlt Inc. Ethylenglykol estery monohydrobenzoporfyrinových derivátů jako fotoaktivní činidla
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
GB9905911D0 (en) * 1999-03-15 1999-05-05 Photocure As Method
GB0018527D0 (en) 2000-07-27 2000-09-13 Photocure Asa Composition
PT1346059E (pt) * 2000-11-29 2012-06-01 Pci Biotech As Internalização fotoquímica para distribuição de moléculas no citosol

Also Published As

Publication number Publication date
CA2430087C (en) 2016-06-28
CN1553958A (zh) 2004-12-08
US20050075268A1 (en) 2005-04-07
US7223600B2 (en) 2007-05-29
CA2430087A1 (en) 2002-06-06
HUP0402260A2 (hu) 2005-02-28
PT1346059E (pt) 2012-06-01
CZ301427B6 (cs) 2010-02-24
EP1346059B1 (en) 2012-05-23
AU2085302A (en) 2002-06-11
KR100980153B1 (ko) 2010-09-03
AU2002220853B2 (en) 2007-06-28
CZ20031791A3 (cs) 2003-10-15
BR0115795A (pt) 2003-08-12
HUP0402260A3 (en) 2005-06-28
CN100558903C (zh) 2009-11-11
KR20080080685A (ko) 2008-09-04
HU229805B1 (en) 2014-07-28
WO2002044396A1 (en) 2002-06-06
PL213560B1 (pl) 2013-03-29
KR20030074632A (ko) 2003-09-19
HK1056573A1 (en) 2004-02-20
EP1346059A1 (en) 2003-09-24
JP2004520021A (ja) 2004-07-08
PL365006A1 (en) 2004-12-27
US8008077B2 (en) 2011-08-30
US20070274953A1 (en) 2007-11-29
ES2383516T3 (es) 2012-06-21

Similar Documents

Publication Publication Date Title
JP4578770B2 (ja) 細胞質中への分子送達のための光化学的内在化
AU2002220853A1 (en) Photochemical internalization for delivery of molecules into the cytosol
JP4922490B2 (ja) 方法
EP1339862B1 (en) Photochemical internalization for virus-mediated molecule delivery into the cytosol
AU2002222104A1 (en) Photochemical internalization for virus-mediated molecule delivery into the cyosol
RU2333246C2 (ru) Фотохимическая интернализация для доставки молекул в цитозоль
HK1056573B (en) Photochemical internalization for delivery of molecules into the cytosol
HK1055137B (en) Photochemical internalization for virus-mediated molecule delivery into the cyosol

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091005

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091109

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20091109

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20091201

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20091201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100810

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100825

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130903

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees